Catalent Content

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years’ industry experience, Catalent has the proven expertise, superior technologies and flexible solutions at the right scale to help ensure successful product development, launch, tech transfer and reliable global clinical and commercial supply. Our team of approximately 14,000 people, at +45 sites, supplies over 73 billion doses of +7,000 products for more than 1,000 customers – or 1 in 20 doses taken by patients globally. At Catalent, we combine deep expertise in the science of drug development and manufacturing with the art of crafting better treatments to deliver successful medicines for our customers and their patients faster.

Email: Solutions@catalent.com
Website: www.catalent.com

Below you'll find on-demand content on various topics:

  • Strategies to Avoid Dangerous Pitfalls in Pharmaceutical Consulting
    • Determining a client’s primary goal is critical to guiding them through the development of their asset. Learn the strategies to avoid costly pitfalls in pharmaceutical consulting and gain inside tips on using CDMOs to deliver solutions to your clients.
  • Early Drug Development: Strategy and Solution
    • "Learn about:
      • the importance of clinically-relevant preclinical models in drug development
      • solubility and bioavailability challenges and formulation approaches to mitigate them
      • identifying key ADME attributes and input parameters for PBPK modeling"
  • How COVID-19 Is Bending the Curve on Vaccine Development and Manufacturing Norms
    • The COVID-19 pandemic is requiring a significant reduction in vaccine development and clinical trial timelines. The stakes are high and it’s all-hands-on-deck for sponsor companies, contract providers, and suppliers who are collaborating to overcome these obstacles. Hear Mike Riley, Catalent Biologics Region President, North America, address challenges in manufacturing scale-up and discuss how partnerships are enabling pharma companies of all sizes to meet unprecedented timelines as they race toward delivering vaccines to patients worldwide.
  • Discover the Latest Funding, Drug Development and Clinical Solutions Strategies
    • In this webcast specifically designed for pharmaceutical and biotech consultants, and early stage development partners, three early drug development industry experts present their insights and techniques to help your clients get their molecules from preclinical to Phase 1.
  • Biologics Drug Product: Strategies for Formulation, Tech Transfer and Delivery System
    • This webinar covers the key considerations for formulation screening of therapeutic proteins with a focus on maintaining protein stability and avoiding aggregation. This is followed by a discussion showing how consistency, planning, and communication are essential elements for a successful biologic drug product technical transfer. The session ends with a presentation of current innovations in injection delivery systems, an update on the demand for large-volume injectors, as well as usability insights on patient delivery methods.
  • Manufacturing Innovation Across New Modalities
    • The successful outcomes delivered by cell and gene therapies coupled with emergence of modalities across nucleic acid therapeutics and microbiomes pose the next challenge for innovators to make these new modalities available at scale. Faster adoption of emerging cutting-edge development and manufacturing technologies will be vital to success and broad accessibility for patients. In this talk, we review and present key areas of technology innovation that have the potential to reshape how these advanced therapeutics are manufactured at scale.
  • Pharma Predictions for 2021
    • Endpoints Editor John Carroll sat down with Catalent CEO John Chiminski to talk about the year ahead, offering their projections for what 2021 holds in store for the biopharma industry.
  • From Candidate to Clinic: Strategies to Accelerate Your Molecule’s Development Path
    • Industry experts  introduce a fast and efficient development process that can help deliver the right clinical candidate, best formulation strategy, and an optimal dosage form to Phase 1. The presentation will also review details of some established data-driven approaches, including physiologically based pharmacokinetic (PBPK) modeling, parallel formulation screening, API sparing techniques, and optimal early dosing strategies that will help avoid development pitfalls and de-risk a molecule’s path to clinic.
  • How to Effectively Work with a Development Partner - From a Consultant Standpoint
    • "Hear from three experienced industry colleagues on the latest tips that will help your clients avoid critical pitfalls in early development of their drugs to best leverage CDMO experts to help manage and mitigate risks for your clients’ programs.
    • Get insider info on how to access top experts and capabilities from the leading development and delivery technology partner that progresses hundreds of molecules through development and launch every year."
  • Building a Flexible, Challenge Resistant and Patient Centric Clinical Supply Chain
    • The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.